No interaction between Gabapentin and phenobarbital, phenytoin, valproic acid, or carbamazepine has been observed.
Coadministration of Gabapentin with oral contraceptives containing norethindrone and/or ethinyl estradiol, does not influence the steady-state pharmacokinetics of either component.
Coadministration of Gabapentin with antacids containing aluminium and magnesium reduces Gabapentin bioavailability by about 20%. It is recommended that Gabapentin be taken at the earliest two hours following antacid administration.
Renal excretion of Gabapentin is unaltered by probenecid.
A slight decrease in renal excretion of gabapentin that is observed when it is coadministered with cimetidine is not expected to be of clinical importance.
300 & 400 mg: Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs.
Laboratory tests: False positive readings were reported with the Ames N-Multi-stix SG dipstick test when gabapentin was added to other anticonvulsant drugs. To determine urinary protein, the more specific sulfosalicylic acid precipitation procedure is recommended.
600 mg: Gabapentin steady-state pharmacokinetics are similar for healthy subjects and patients with epilepsy receiving these antiepileptic agents.